FDA Device recall Z-2201-2021
Synchron CX/DX/LX Beta-Hydroxybutyrate . in vitro diagnostic reagent
- FDA Device
- Class III
- terminated
- Published 2021-08-11
On 2021-08-11 the FDA classified a Class III recall of Synchron CX/DX/LX Beta-Hydroxybutyrate . in vitro diagnostic reagent by Stanbio Laboratory, citing deterioration in the stability of the reagents which has resulted in lower than expected or out of range Quality Control values.
Read the official FDA Device notice
| Agency | FDA Device |
|---|---|
| Recall number | Z-2201-2021 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2021-07-12 |
| Published | 2021-08-11 |
| Last updated | 2026-09-13 11:56 UTC |
| Company | Stanbio Laboratory |
| Distribution | US |
Product
Synchron CX/DX/LX Beta-Hydroxybutyrate . in vitro diagnostic reagent.
Reason
Deterioration in the stability of the reagents which has resulted in lower than expected or out of range Quality Control values.
Identifiers
| code_info | Catalog Number/Product Description: B2440-180/Synchron CX/DX/LX ¿-Hydroxybutyrate LiquiColor Device Identifier: 00657498000526 Lot Numbers: 161020; |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:56 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-2201-2021%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.